Taencom: CKBA Cream Rose Acne Indication Application for New Drug Clinical Trial Obtained Acceptance Letter

On the afternoon of July 18th, Taian Kang announced that its holding subsidiary, Jiangsu Bochuangyuan Biomedicine Technology Co., Ltd., recently received an acceptance notification issued by the National Medical Products Administration, approving the submission of CKBA cream for the treatment of rosacea for the conduct of Phase II/III seamless adaptive clinical trials. As of now, there has not yet been a Class 1 innovative drug approved for the treatment of rosacea in China. The acceptance of the application for Phase II/III seamless adaptive clinical trials of CKBA cream for rosacea will not have a significant impact on the company's short-term financial status or operational performance.